Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension (Q38080812)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 December 2012

Language	Label	Description	Also known as
English	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension	scientific article published on 20 December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

28 August 2017

Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension (English)

1 reference

Europe PubMed Central

28 August 2017

0 references

arterial hypertension

0 references

0 references

circulatory system

1 reference

based on heuristic

inferred from title

Donald Lloyd-Jones

object named as

Donald Lloyd-Jones

6

0 references

Lawrence J Beilin

3

object named as

Lawrence J Beilin

1 reference

Europe PubMed Central

28 August 2017

author name string

Lewis Landsberg

1

1 reference

Europe PubMed Central

28 August 2017

Louis J Aronne

2

1 reference

Europe PubMed Central

28 August 2017

Valerie Burke

4

1 reference

Europe PubMed Central

28 August 2017

Leon I Igel

5

1 reference

Europe PubMed Central

28 August 2017

James Sowers

7

1 reference

Europe PubMed Central

28 August 2017

publication date

20 December 2012

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

28 August 2017

21

1 reference

Europe PubMed Central

28 August 2017

8-24

1 reference

Europe PubMed Central

28 August 2017

1

1 reference

Europe PubMed Central

28 August 2017

Prevalence and trends in obesity among US adults, 1999-2008

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Relation of body fat distribution to metabolic complications of obesity.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Hyperinsulinemia. A link between hypertension obesity and glucose intolerance

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why).

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Relation of obesity and diet to sympathetic nervous system activity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Body fat and sympathetic nerve activity in healthy subjects.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Receptor-mediated regional sympathetic nerve activation by leptin.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The role of leptin in human obesity and disease: a review of current evidence

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Chronic leptin infusion increases arterial pressure.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

High plasma immunoreactive leptin level in essential hypertension

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Weight loss and the renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Obesity, sleep apnea, aldosterone, and hypertension

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The role of obesity in the pathogenesis of hypertension

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Body mass index and angiotensin-dependent control of the renal circulation in healthy humans

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Sleep as a mediator of the relationship between socioeconomic status and health: a hypothesis

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Sympathetic nerve activity in obstructive sleep apnoea

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Obesity, Sleep Apnea, and Hypertension

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Fetal programming of coronary heart disease

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Elevated sympathetic nerve activity: the link between low birth size and adult-onset metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effect of Body Mass Index Changes Between Ages 5 and 14 on Blood Pressure at Age 14

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Hypertension in adults across the age spectrum: current outcomes and control in the community

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Cross-classification of JNC VI Blood Pressure Stages and Risk Groups in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The lifetime risk of stroke: estimates from the Framingham Study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Lifetime Risk for Developing Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The progression from hypertension to congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Body mass index and risk for end-stage renal disease

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Impact of sleep debt on metabolic and endocrine function

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Sleepless in America: a pathway to obesity and the metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Obesity and metabolic syndrome in circadian Clock mutant mice

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: the Bogalusa Heart Study.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Childhood adiposity, adult adiposity, and cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Tracking of obesity-related behaviours from childhood to adulthood: A systematic review

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Perinatal and childhood origins of cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Longitudinal modelling of body mass index from birth to 14 years.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

A controlled evaluation of a fitness and nutrition intervention program on cardiovascular health in 10- to 12-year-old children.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

A controlled trial of health promotion programs in 11-year-olds using physical activity "enrichment" for higher risk children.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Prevention of Overweight in Infancy (POI.nz) study: a randomised controlled trial of sleep, food and activity interventions for preventing overweight from birth

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Cardiovascular health promotion for children: a model for a Parish (County)-wide program (implementation and preliminary results).

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

A randomised controlled trial for overweight and obese parents to prevent childhood obesity--Early STOPP (STockholm Obesity Prevention Program).

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Assessing the efficacy of the Healthy Eating and Lifestyle Programme (HELP) compared with enhanced standard care of the obese adolescent in the community: study protocol for a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

EPODE approach for childhood obesity prevention: methods, progress and international development

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Global nutrition transition and the pandemic of obesity in developing countries

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Closing the energy gap to prevent weight gain in China.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Translational research: bridging the gap between long-term weight loss maintenance research and practice

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Prevalence of obesity among US preschool children in different racial and ethnic groups

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Lifestyle and pharmacological approaches to weight loss: efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Dietary approaches to the treatment of obesity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

ASH position paper: Dietary approaches to lower blood pressure

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Vegetarian diet components, protein and blood pressure: which nutrients are important?

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT).

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Suboptimal nutritional intake for hypertension control in 4 ethnic groups

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Does physical activity prevent weight gain--a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The effect of physical activity on body weight

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Sedentary behaviors and health outcomes among adults: a systematic review of prospective studies

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Alcohol is bad for blood pressure

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Alcohol consumption and body weight: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

What is the most effective way to maintain weight loss in adults?

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Cognitive and behavioral approaches in the treatment of obesity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Associations of internet website use with weight change in a long-term weight loss maintenance program

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus--a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Best strategies for hypertension management in type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The metabolic syndrome in hypertension: European society of hypertension position statement

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Metabolic sequelae of β-blocker therapy: weighing in on the obesity epidemic?

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Body weight changes with beta-blocker use: results from GEMINI.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Nebivolol in obese and non-obese hypertensive patients.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Hypothalamic control of feeding

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Role of central melanocortin pathways in energy homeostasis

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Cold-activated brown adipose tissue in healthy men

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Pharmacological therapies for obesity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Drug treatment of the overweight patient

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Pramlintide and the treatment of diabetes: a review of the data since its introduction

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Bariatric surgery: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Promoting healthy lifestyles and decreasing childhood obesity: increasing physician effectiveness through advocacy

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Probability of stroke: a risk profile from the Framingham Study

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Fetal and Childhood Growth and Hypertension in Adult Life

1 reference

https://api.crossref.org/works/10.1002%2FOBY.20181

21 January 2018

Identifiers

10.1002/OBY.20181

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38080812&oldid=2062401759"